Cargando…
The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic dat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167767/ https://www.ncbi.nlm.nih.gov/pubmed/33919650 http://dx.doi.org/10.3390/curroncol28020146 |
_version_ | 1783701758376148992 |
---|---|
author | Varghese, Chris Immanuel, Tracey Ruskova, Anna Theakston, Edward Kalev-Zylinska, Maggie L. |
author_facet | Varghese, Chris Immanuel, Tracey Ruskova, Anna Theakston, Edward Kalev-Zylinska, Maggie L. |
author_sort | Varghese, Chris |
collection | PubMed |
description | Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic data for PV, ET and PMF collected by the New Zealand Cancer Registry (NZCR) between 2010 and 2017. Results: We found that the NZCR capture rates were lower than average international incidence rates for PV and ET, but higher for PMF (0.76, 0.99 and 0.82 per 100,000, respectively). PV patients were older and had worse outcomes than expected, which suggests these patients were reported to the registry at an advanced stage of their disease. Polynesian patients with all MPN subtypes, PV, ET and PMF, were younger than their European counterparts both at the time of diagnosis and death (p < 0.001). Male gender was an independent risk factor for mortality from PV and PMF (hazard ratios (HR) of 1.43 and 1.81, respectively; p < 0.05), and Māori ethnicity was an independent risk factor for mortality from PMF (HR: 2.94; p = 0.006). Conclusions: New Zealand Polynesian patients may have increased genetic predisposition to MPN, thus we advocate for modern genetic testing in this ethnic group to identify the cause. Further work is also required to identify modifiable risk factors for mortality in MPN, in particular those associated with male gender and Māori ethnicity; the results may benefit all patients with MPN. |
format | Online Article Text |
id | pubmed-8167767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81677672021-06-02 The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry Varghese, Chris Immanuel, Tracey Ruskova, Anna Theakston, Edward Kalev-Zylinska, Maggie L. Curr Oncol Article Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic data for PV, ET and PMF collected by the New Zealand Cancer Registry (NZCR) between 2010 and 2017. Results: We found that the NZCR capture rates were lower than average international incidence rates for PV and ET, but higher for PMF (0.76, 0.99 and 0.82 per 100,000, respectively). PV patients were older and had worse outcomes than expected, which suggests these patients were reported to the registry at an advanced stage of their disease. Polynesian patients with all MPN subtypes, PV, ET and PMF, were younger than their European counterparts both at the time of diagnosis and death (p < 0.001). Male gender was an independent risk factor for mortality from PV and PMF (hazard ratios (HR) of 1.43 and 1.81, respectively; p < 0.05), and Māori ethnicity was an independent risk factor for mortality from PMF (HR: 2.94; p = 0.006). Conclusions: New Zealand Polynesian patients may have increased genetic predisposition to MPN, thus we advocate for modern genetic testing in this ethnic group to identify the cause. Further work is also required to identify modifiable risk factors for mortality in MPN, in particular those associated with male gender and Māori ethnicity; the results may benefit all patients with MPN. MDPI 2021-04-18 /pmc/articles/PMC8167767/ /pubmed/33919650 http://dx.doi.org/10.3390/curroncol28020146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Varghese, Chris Immanuel, Tracey Ruskova, Anna Theakston, Edward Kalev-Zylinska, Maggie L. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title | The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title_full | The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title_fullStr | The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title_full_unstemmed | The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title_short | The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry |
title_sort | epidemiology of myeloproliferative neoplasms in new zealand between 2010 and 2017: insights from the new zealand cancer registry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167767/ https://www.ncbi.nlm.nih.gov/pubmed/33919650 http://dx.doi.org/10.3390/curroncol28020146 |
work_keys_str_mv | AT varghesechris theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT immanueltracey theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT ruskovaanna theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT theakstonedward theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT kalevzylinskamaggiel theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT varghesechris epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT immanueltracey epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT ruskovaanna epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT theakstonedward epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry AT kalevzylinskamaggiel epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry |